Antidote’s Business Development Leader Dave Mauro Named to the 2021 PharmaVOICE 100

We’re thrilled to share that Antidote’s Executive Vice President of Business Development, Dave Mauro, has been named to this year’s PharmaVOICE 100. For sixteen years, the PharmaVOICE 100 has recognized the 100 most inspiring, motivational, and transformational individuals in the life sciences industry as identified by the global community. 

Dave joined our team about a year ago, at a time when the medical research landscape was full of uncertainty. With an eye toward the future, his focus has been on adapting our business development model for a post-COVID world. He immediately began identifying creative ways we can provide value to our clients, and taking on specific sponsor needs such as diversity in recruitment and support of contactless or decentralized trials. You can read more about Dave’s contributions to Antidote and clinical trial recruitment here.

With a growing team and ever-evolving offerings, Antidote continues to expand its capabilities to meet the needs of today’s researchers. If you’re looking for innovative solutions to enhance recruitment for your clinical trial, please get in touch below.